Abstract. Gastric cancer is the third most frequent cause of cancer-associated mortality and almost all patients who respond initially to cisplatin (DDP) later develop drug resistance, indicating multi-drug resistance (MDR) is an essential aspect of the failure of treatment. The natural diterpenoid component Oridonin (Ori) has exhibited efficient inhibition in several types of human cancer. However, the effect and potential mechanism of Ori-reversed MDR in human gastric cancer has not been fully elucidated. In the present study, it was found that Ori significantly suppressed DDP-resistant human SGC7901/DDP cell proliferation, growth and colony formation, causing increased caspase-dependent apoptosis, decreased expression of P-glycoprotein (P-gp), encoded by the MDR gene, multi-drug resistance-associated protein (MRP1), and cyclin D1. SGC7901/DDP cells were cultured with different groups of drugs (Ori, DDP alone, or the combination of Ori and DDP). The drug sensitivity, cell apoptosis and effects on MDR were detected by MTT assay and western blot analysis. The results revealed that Ori is able to reverse the DDP resistance and has a clear synergistic effect with DDP in SGC7901/DDP cells by decreasing the levels of P-gp, MRP1, cyclin D1 and cancerous inhibitor of protein phosphatase 2A. Thus, Ori may be a novel effective candidate to treat DDP-resistant human gastric cancer cells.
Introduction
Gastric cancer is one of the most common cancers in Eastern Asia, including China, Japan and South Korea, and Eastern Europe (1) . The incidence and mortality of gastric cancer have declined markedly over the past half-century in the majority of developed countries, but it remains the second most common cause of cancer-associated mortality in the world. An estimated 28,000 incident cases (17, 750 in males and 10,250 in females) of gastric cancer will be diagnosed in 2017, and 10,960 mortalities (6,720 in males and 4,240 in females) are estimated to occur from the disease (2) . In China, approximately two-thirds of patients develop advanced or metastatic disease, and >50% have recurrent disease following curative surgery (3) . Systematic chemotherapy plays a critical role in the treatment of gastric cancer. Cisplatin (DDP) has been commonly used in the treatment of gastric cancer (4) . Despite an initial response to surgical debulking and front-line platinum chemotherapy, the majority of tumors eventually develop a drug resistant relapse selected during the course of therapy. The reasons for drug resistance are complicated and several previous studies have aimed to explore the question (1) . The development of multidrug resistance (MDR) to cancer chemotherapy is a major obstacle to the effective treatment of advanced gastric cancer (5) . Additionally, the mechanism of MDR remains obscure. Mechanisms including increased expression of P-glycoprotein (P-gp) and MDR-associated protein (MRP), cell cycle arrest, increased DNA damage repair and resistance of tumor cells to apoptosis may account for MDR (6) . Restoring DDP sensitivity by reversing MDR would be an effective method of treatment.
Oridonin (Ori; Fig. 1A ), a bitter tetracyclin diterpenoid compound, may be isolated from Rabdosia rubescens, Isodon japonicus Hara and Isodon trichocarpus, which are widely distributed in China, Japan and Korea (7) . Studies show that Ori exhibits potent anticancer activity against a wide range of cancer cell types, including those from prostate, breast, pancreatic and non-small cell lung cancer, leukemia, glioblastoma multiforme and human melanoma cells (8) (9) (10) (11) (12) (13) . However, to the best of our knowledge, no study has shown the effect and the potential mechanism of Ori reversing MDR of human gastric cancer. Therefore, in the present study, the antitumor effects and possible mechanisms of Ori on the DDP-resistant human gastric cancer SGC7901/DDP cell line were investigated.
Materials and methods

Reagents.
Ori with a purity of up to 98% was purchased from Shanghai YuanYe BioTechnology Co., Ltd. (Shanghai, China). Ori was dissolved in dimethyl sulfoxide (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at a stock solution of 100 mM and stored at -20˚C. DDP was purchased from Sigma-Aldrich (Merck KGaA).
Cell culture. Human cisplatin-resistant gastric cancer cell line SGC7901/DDP and human gastric cancer cell line SGC7901 were purchased from American Type Culture Collection (Manassas, VA, USA). SGC7901/DDP cells were grown in RPMI-1640 (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with fetal bovine serum (FBS; Hyclone; GE Healthcare, Logan, UT, USA), 500 ng/ml DDP, penicillin (50 U/ml), and streptomycin (50 U/ml), and incubated in a humidified atmosphere with CO 2 at 37˚C. SGC7901 cells were grown in RPMI-1640 with FBS and penicillin (50 U/ml), and streptomycin (50 U/ml) and incubated in a humidified atmosphere with CO 2 at 37˚C. Soft-agar colony formation assay. Cells were suspended in 1 ml of RPMI-1640 containing 0.3% low-melting-point agarose (Amresco, Solon, OH, USA) and 10% FBS, and plated on a bottom layer containing 0.6% agarose and 10% FBS in 6-well plate in triplicate. After 2 weeks, the plates were stained with 0.2% gentian violet (Sigma-Aldrich; Merck KGaA) and the colonies were counted under light microscopy (IX70; Olympus Corporation, Tokyo, Japan) (15) .
Apoptosis determination by DAPI staining. Approximately 2x10 5 cells/well were added to a 12-well plate and treated with Ori (0, 20, 30, 40 µM) for 24 h. Cells in each treatment and control were then stained by DAPI, examined under fluorescence microscopy and images were captured, as previously described (16) .
Western blot analysis. Cell pellets were lysed in radioimmunoprecipitation assay buffer containing 50 mM Tris (pH 8.0), 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% NP-40, 1 mM DTT, 1 mM NaF, 1 mM sodium vanadate and 1 mM PMSF (Sigma-Aldrich; Merck KGaA), and 1% protease inhibitor cocktail (Merck KGaA). Protein extracts were quantitated and loaded onto 8-12% sodium dodecyl sulfate polyacrylamide gel, electrophoresed, and transferred to a polyvinylidene difluoride membrane (Merck KGaA). The membrane was incubated overnight at 4˚C with primary antibody, washed, and then incubated with goat anti-rabbit or anti-mouse immunoglobulin G (H&L) horseradish peroxidase (HRP)-conjugated washed, and incubated with HRP-conjugated secondary antibody (1:10,000 dilution; catalog no. E030120-01 and E030110-01; EarthOx, LLC, San Francisco, CA, USA) for 1.5 h at room temperature for 1.5 h. Detection was performed by using a SuperSignal ® West Pico Trial kit (catalog no. QA210131; Pierce Biotechnology, Inc., Rockford, IL, USA). The antibodies used were as follows: Anti-MRP1 (1:500 dilution; catalog no. sc-13960), anti-cyclin D1 (1:500 dilution; catalog no. sc-2044), anti-CIP2A (1:500 dilution; catalog no. sc-80662), anti-Akt (1:500 dilution; catalog no. sc-8312) and anti-phosphorylated (p) Akt (Ser473; 1:500 dilution; catalog no. sc-7985; Santa Cruz Biotechnology, Inc., Dallas, TX, USA); anti-caspase-3 (casp-3; 1:1,000 dilution; catalog no. 9662), anti-PARP (1:1,000 dilution; catalog no. 9542), anti-catalytic subunit of PP2A (PP2Ac; 1:1,000 dilution; catalog no. 2038), anti-extracellular signal-regulated kinase (ERK) 1/2 (1:1,000 dilution; catalog no. 9102) and anti-pERK1/2 (Thr202/Tyr204; 1:1,000 dilution; catalog no. 9101) (Cell Signaling Technology, Inc.); anti-P-gp (1:2,000 dilution; catalog no. ab170904) (Abcam, Cambridge, UK); and anti-GAPDH (1:5,000 dilution; catalog no. M20006; Abmart, Shanghai, China).
Statistical analysis.
All experiments were repeated at least three times and the data were presented as the mean ± standard deviation unless stated otherwise. Differences between data groups were evaluated for significance using Student's t-test for unpaired data or one-way analysis of variance and Bonferroni post hoc test. P<0.05 was considered to indicate a statistically significant difference.
Results
Effects of Ori on SGC7901 and SGC7901/DDP gastric cancer cells. SGC7901 and SGC7901/DDP cells were seeded onto 96-well plates for 24 h and then treated with different concentrations of Ori (Fig. 1B and C) . After 24 h, the cell viability was evaluated by the MTT assay and absorbance at 490 nm was measured. It was found that Ori had moderate cytotoxicity to SGC7901 and SGC7901/DDP cells with a half-maximal inhibitory concentration (IC 50 ) of 13.84 and 36.35 µM (Table I) . By Trypan blue exclusion assay, it was found that Ori rapidly reduced the growth of SGC7901/DDP cells (Fig. 1D) . The effect of Ori on cell colony formation activity was investigated, and the results showed that Ori significantly inhibited the clonogenic ability of SGC7901/DDP (Fig. 1E) . These results suggested that Ori inhibited the anchorage-dependent (cell proliferation) and anchorage-independent (colony formation) growth of SGC7901/DDP cells.
Ori induces apoptosis in SGC7901/DDP cells. As aforementioned, the mechanism underlying the inhibition effect of Ori on SGC7901/DDP cells was investigated. The cell death is reminiscent of the phenomena induced by apoptosis. Subsequently, whether Ori induces apoptosis of the SGC7901/DDP cells was assessed. Firstly, the morphological changes of the nucleus were investigated by DAPI staining. As shown in Fig. 2A , nuclear condensation and fragmentation was identified following Ori treatment, which are typical changes in cell apoptosis. Furthermore, western blot analysis was used to detect the activation of the casp-3 effector caspase and its substrate, PARP (Fig. 2B) . Ori was demonstrated to induce a significant dose-dependent decrease in pro-casp-3 and the cleavage of PARP, in SGC7901/DDP cells, indicating that Ori induced caspase-dependent apoptosis. Ori affected the expression of P-gp, MRP1 and cyclin D1. To investigate the mechanism by which Ori induces reversing MDR of SGC7901/DDP cells, the expression levels of P-gp, MRP1 and cell cycle protein cyclin D1 were detected by western blot analysis (Fig. 3) . The results indicated that P-gp, MRP1 and cyclin D1 expression of SGC7901/DDP cells were downregulated by treatment with increasing concentrations of Ori. The decreased expression of P-gp and MRP1 in SGC7901/DDP cells may contribute to the reversal of chemoresistance.
Ori inhibited Akt signaling pathway-associated molecules.
MDR occurs due to the positive feedback signaling loops generating cancer extreme robustness. Akt is a cancer MDR locus. Targeting that locus by oxidant/antioxidant balance modulation, positive feedback loops are converted into negative feedback loops, leading to disappearance of MDR (17) . The present study examined the effect of Ori on phosphorylated (p)Akt in SGC7901/DDP cells. It was shown that treatment with Ori resulted in downregulation of pAkt, but not phosphorylated (p)ERK1/2 (Fig. 4) . PP2A, one of the main serine-threonine phosphatases, has a critical role in the regulation of cell-cycle progression, survival and differentiation by negatively regulating the PI3K/Akt pathway, and dephosphorylating and inactivating mitogen-activated protein kinase kinase 1 and ERK family kinases (18) . The present study tested the effects of Ori on PP2Ac (catalytic subunit), and found that Ori upregulated PP2Ac and downregulated cancerous inhibitor of protein phosphatase 2A (CIP2A), a critical oncoprotein in several types of cancer (19) , at protein level (Fig. 4) . Thus, the present study concluded that the inhibitory effect of Ori on the MDR of SGC7901/DDP cells may be partially due to the regulation of the CIP2A/PP2A/Akt signal cascade.
Ori exerts synergistic effect combining with DDP in SGC7901/DDP cells. The low toxicity (10 and 20 µM) doses were selected for additional experiments to detect whether Ori can reverse the resistance of SGC7901/DDP cells to low doses of DDP (10 and 20 µM) (Fig. 5A) . Ori in combination with DDP had a greater effect on the SGC-7901/DDP cells compared with DDP or Ori alone (P<0.05). The combination index (CI) value was also analyzed using CalcuSyn software (version 2.1; Biosoft, Cambridge, UK) and found that the CI values were <1 (Table III) , which indicated that Ori and DDP played a synergistic effect in SGC7901/DDP cells. Western blot analysis further confirmed the synergistic effect and found that Ori and DDP combination resulted in elevated levels of casp-3 activation, cleavage of PARP, and decreased P-gp, MRP1, cyclin D1 and CIP2A expression (Fig. 5B) .
Discussion
Gastric cancer is a major type of cancer worldwide and its incidence rate is among the three most frequent neoplasms in China (1). Gastric cancer is also the third most frequent cause of cancer-associated mortality following lung and liver cancer in males, and following breast and lung cancer in females (1,2).
To improve the outcome of gastric cancer, different treatment strategies have been evaluated, including chemotherapy, radiotherapy and extended resection (20) . Chemotherapy is the most common treatment of choice for gastric cancer, but its application is limited due to drug resistance. DDP is a platinum chemotherapeutic agent that is widely used in several malignancies and is beneficial in certain patients, but treatment with DDP may cause DDP resistance (21) . Therefore, identification and development of novel drugs that can overcome the DDP resistance is required to prolong the overall survival time of gastric cancer patients. To overcome such resistance, exploring novel compounds is urgent. Compounds from natural sources constitute an indispensable candidate drug library for pharmacotherapy. In the present study, the efficacy of the combination of Ori, a bitter tetracyclin diterpenoid compound isolated from traditional medicinal herbs (8) , and DDP on the gastric cancer SGC7901/DDP cell line was investigated. Inhibition of cell proliferation is an efficient strategy in cancer therapy. In this present study, Ori was shown to inhibit the proliferation (Fig. 1C), cell viability (Fig. 1D ) and soft-agar colony formation (Fig. 1E ) of the gastric cancer SGC7901/DDP cell line.
Evading apoptosis is one of the hallmarks of drug resistance, and targeting apoptosis has become a cancer therapeutic strategy (22) . The present study found that the change in cellular morphology and nucleus condensation, which were typical characters of apoptosis ( Fig. 2A) . Therefore, Ori may have the ability to induce cell apoptosis. The extrinsic and intrinsic apoptotic pathways that ultimately lead to activation of effector caspases (casp-3, -2 and -7) have been characterized (23,24) . The decrease in pro-casp-3 expression and the proteolysis of PARP (Fig. 2B) indicate that casp-3 is activated. Thus, Ori may trigger apoptosis by activating the casppasedependent apoptosis pathway.
A number of experimental strategies to overcome DDP resistance act at the preclinical or clinical levels, including the introduction of pro-apoptotic genes and the inhibition of antioxidants that protect against oxidative stress and prevent damage to cells (25, 26) . Of particular significance are the combinations of chemotherapy drug treatments with other drugs, radiation and the emerging gene therapy regimens. The effect of the combination of Ori and DDP on the SGC7901/DDP cells was investigated, and it was identified that Ori in combination with DDP had an improved effect compared with DDP or Ori alone. Following treatment with Ori (10 and 20 µM), the IC 50 of DDP to the SGC7901/DDP cells was significantly reduced from 34.71 µM to 27.87 and 14.29 µM by 1.25-fold and 2.43-fold, respectively (Table II) . The RI was 2.43 in the SGC7901/DDP parent group, 1.95 in the SGC7901/DDP Ori 10 µM group and 1.00 in the SGC7901/DDP Ori 20 µM group. Furthermore, the present study explored the mechanisms of Ori in reversing DDP resistance.
Drug resistance is largely mediated through overexpression of MDR, MRP, drug resistance protein and proteasome subunits, increases in antioxidant defenses, and TOP2 activity; these results have been widely verified (27) (28) (29) . In addition, suppression of cyclin D1 levels has been shown to potentiate the response of human pancreatic cancer cells to DDP (30) . The present study identified that the treatment with Ori was able to reverse the MDR of the SGC7901/DDP cells via the downregulation of P-gp, MRP1 and cyclin D1 (Fig. 3) .
To assess whether Akt and CIP2A are the targets of Ori, their activation and expression in SGC7901/DDP cells treated with Ori was measured. Akt phosphorylation and CIP2A expression were inhibited by treatment with Ori (Fig. 4) . This suggests that Ori reverses MDR, at least in part, through suppression of the CIP2A/PP2A/Akt signaling cascade.
The low toxicity (10 and 20 µM) doses of Ori and DDP were combined to investigate a possible synergistic effect, and the results showed that Ori could significantly elevate DDP anti-tumor efficiency, and the CI was <1, as calculated by CalcuSyn software (version 2.1). Additionally, the expression of full-length casp-3 was reduced and PARP was cleaved. Additionally, the MDR genes P-gp and MRP1, and CIP2A were also significantly inhibited by combined treatment with Ori and DDP. Cisplatin, which reacts with DNA and forms DNA adducts, is the main drug for treatment of gastric cancer (26) . Notably, the two drugs, which have different mechanisms, synergistically inhibited cell growth. The combination of these drugs may have clinic potential in cisplatin-resistant human gastric cancer treatment.
In conclusion, the present results have confirmed that Ori combination with DDP could overcome chemoresistance of SGC7901/DDP cells. One possible mechanism is that Ori induced apoptosis, modulated drug resistance and cell cycle proteins, P-gp, MRP1 and cyclin D1. The inhibition of the CIP2A/PP2A/Akt signal cascade pathway is a key role in the process of Ori plays its function. Ori may be a promising new drug due to its ability to reverse MDR in gastric cancer. 
